Lyell Immunopharma (LYEL) Financials

Lyell Immunopharma’s financial profile remains heavily dependent on its cash and investment portfolio. The company generated only $4,000 of revenue in Q2 2026, compared with $2,000 in Q1 2026 and $8,000 in Q2 2025. With essentially no commercial revenue, operating results continue to be driven by research and development spending rather than product sales.

Q2 2026 research and development expense increased to $39.5 million from $36.6 million in Q1, while selling, general and administrative expense was relatively stable at $9.6 million. Total operating expenses rose to $47.3 million, producing an operating loss of $47.3 million. The net loss was $44.8 million, compared with a $24.2 million loss in Q1, as Q1 benefited from $20.1 million of other income versus only $2.6 million in Q2.

Cash usage improved modestly. Net cash used in operating activities was $33.9 million in Q2 2026, down from $38.5 million in Q1 and broadly comparable with $34.5 million in Q2 2025. However, the company’s net loss and operating cash burn remain persistent, indicating that Lyell has not yet reached a self-funding stage.

Lyell ended Q2 with $73.0 million of cash and equivalents, $131.1 million of short-term investments and $42.9 million of long-term investments. Combined cash and investments totaled approximately $247.0 million, down from roughly $279.2 million in Q1 and $315.8 million in Q2 2025. At Q2’s operating cash-burn rate, this liquid-asset balance provides a substantial, but declining, financial runway.

The balance sheet remains relatively strong from a leverage perspective. Total liabilities were $77.3 million against $233.8 million of equity, and current assets of $213.5 million exceeded current liabilities of $39.9 million by a wide margin. Still, total assets have declined from $619.2 million in Q3 2024 to $311.2 million in Q2 2026, reflecting ongoing losses and the consumption of cash and investments.

• Strong near-term liquidity: Approximately $247.0 million in cash, short-term investments and long-term investments remained available at June 30, 2026.
• Low balance-sheet leverage: Total liabilities of $77.3 million were modest relative to $233.8 million of shareholders’ equity, with no preferred stock or reported commitments and contingencies.
• Operating cash burn improved sequentially: Cash used in operating activities fell to $33.9 million in Q2 from $38.5 million in Q1 2026.
• Research spending is continuing: R&D investment rose to $39.5 million in Q2 from $36.6 million in Q1, supporting Lyell’s development efforts even though it increases near-term losses.
• Investment income provides some support: Interest and investment income contributed $2.2 million in Q2, but this is not a substitute for recurring operating revenue.
• Investment portfolio activity is significant: Lyell purchased $53.5 million and sold or received maturities of $69.4 million of investments during Q2, indicating active management of its liquidity portfolio.
• Revenue remains negligible: Q2 revenue of $4,000 was insignificant compared with $47.3 million of quarterly operating expenses, leaving the company dependent on outside capital and its existing liquidity.
• Losses remain substantial: The Q2 net loss widened to $44.8 million from $24.2 million in Q1, while the operating loss increased to $47.3 million from $44.3 million.
• Cash and investments are declining: Combined cash and investments fell by approximately $32.2 million from Q1 and by approximately $68.8 million from Q2 2025.
• Potential dilution risk: Weighted-average basic shares increased to 23.4 million in Q2 from 21.9 million in Q1 and 14.8 million in Q2 2025. The company also raised $51.7 million through common equity issuance in Q1, highlighting the possibility of future financing-related dilution.